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ABSTRACT
Nonalcoholic fatty liver disease (NAFLD) represents a burgeoning worldwide epidemic whose 
etiology reflects multiple interactions between environmental and genetic factors.  Here we 
review the major pathways and dominant genetic modifiers known to be relevant players in 
human NAFLD and which may determine key components of the heritability of distinctive disease 
traits including steatosis and fibrosis.  In addition, we have employed general assumptions which 
are based on known genetic factors in NAFLD to build a systems biology prediction model that 
includes functional enrichment.  This new prediction model highlights additional complementary 
pathways that represent plausible intersecting signaling networks that we define here as a 
NAFLD-Reactome.  We review the evidence connecting variants in each of the major known 
genetic modifiers (variants in PNPLA3, TM6SF2, MBOAT7, GCKR and HSD17B13) to NAFLD and 
expand the associated underlying mechanisms using functional enrichment predictions, based on 
both preclinical and cell based experimental findings.  These major candidate gene variants 
function in distinct pathways, including substrate delivery for de-novo lipogenesis; mitochondrial 
energy utilization; lipid droplet assembly, lipolytic catabolism and fatty acid 
compartmentalization; and VLDL assembly and secretion.  The NAFLD-Reactome model expands 
these pathways and allows for hypothesis testing as well as serving as a discovery platform for 
druggable targets across multiple pathways that promote NAFLD development and which 
influence several progressive outcomes.  In conclusion, we summarize the strengths and 
weaknesses of studies implicating selected variants in the pathophysiology of NAFLD and 
highlight opportunities for future clinical research and pharmacologic intervention, as well as the 
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Importance of Genetic pathways in NAFLD:
Nonalcoholic fatty liver disease (NAFLD) represents the most prevalent liver disease in the world, 
whose health and economic impact is now widely recognized as a global burden (1). The 
relentlessly increasing incidence of NAFLD is associated with the burgeoning worldwide epidemic 
of obesity (2), but in addition, the past two decades have witnessed increasing awareness of the 
role of genetic factors in both the etiology and progression of this multifactorial disease.  
Significant advances in understanding the heritable contribution to NAFLD have been achieved 
through combinations of stringent patient selection (refining phenotypic variation from families 
and from twin studies) and with the applications of genome-wide association studies (GWAS) and 
exome sequencing within large populations.  However, because NAFLD is common and highly 
prevalent among obese subjects, and because obesity and NAFLD are both independently 
associated with type 2 diabetes, assigning genetic linkage to distinctive traits among NAFLD 
subjects is influenced by modifiers associated with each of these diseases.
Earlier retrospective studies from different US centers reported familial clustering of phenotypes 
among kindreds in which affected members manifested advanced features of NAFLD, including 
nonalcoholic steatohepatitis (NASH) and cirrhosis (3, 4).  Among the shared features was that 
greater than 80% of first-degree relatives of probands with NASH exhibited glucose intolerance 
and insulin resistance, with or without overt type 2 diabetes (3, 4), findings replicated in studies 
showing increased prevalence of insulin resistance in family members with NAFLD (5).  Studies in 
313 Finnish twins selected from a population cohort showed that ~60% of the variation in serum 
alanine aminotransferase (ALT) levels was heritable and revealed higher ALT levels in 
monozygotic versus dizygotic twins (6), suggesting distinctive genetic contributions to specific 
traits among NAFLD patients.  Those findings were amplified through studies from US 
populations showing that both hepatic steatosis, assessed by magnetic resonance imaging 
proton-density fat fraction (MRI-PDFF) and also hepatic fibrosis, assessed by magnetic resonance 
elastography (MRE), were each significantly correlated among monozygotic twins (7).  Those 
findings are in line with work showing that diabetes is strongly associated with the risk of NASH 
and advanced fibrosis in NAFLD patients (8). Cross-sectional analyses revealed that probands of 
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(17.9%) than in first degree relatives of age-matched controls without features of NAFLD 
(1.4%)(9).  Even first-degree relatives of NAFLD probands without cirrhosis exhibited higher rates 
of fibrosis (12%), suggesting that heritable factors play an important role in both the etiology and 
progression of NAFLD.  Those conclusions are substantiated by findings in pediatric populations, 
where steatosis was found in 17% of siblings and 37% of parents of overweight children and in 
59% of siblings and 78% of parents of children with NAFLD (10).  Considered together, heritability 
estimates for various traits associated with NAFLD (obesity, metabolic syndrome, insulin 
resistance, hepatic steatosis, fibrosis) range from 30-75% (11-13) although the variants identified 
for certain traits, for example steatosis, are not uniformly associated with other features such as 
fibrosis or insulin resistance, suggesting genetic heterogeneity within pathways that influence 
selected traits (13).
In addition and as alluded to above, because complex traits reflect the interplay between host 
genetic and environmental factors, a complete understanding of the genetic pathways involved 
in NAFLD requires that networks linking various traits to environmental modifiers (for example 
smoking (14)) be considered, as well as other networks that may synergize with NAFLD traits, 
such as obesity, cardiometabolic disorders (15, 16) and insulin resistance (17).  Accordingly, the 
genetic contribution to NAFLD phenotypes reflects a spectrum of Mendelian monogenic and 
polygenic variants as well as mitochondrial variants.  Among polygenic traits (such as obesity, 
Figure 1), variants in many genes each contribute variable but small effects and it is the 
combination of these effects that determines phenotypic manifestations.  Conversely, 
monogenic disorders reflect mutations and/or variants in single genes, typically with Mendelian 
recessive or dominant inheritance. Pedigree analyses in monogenic disorders typically reveals 
multiple affected family members and the effects of these isolated mutations/variants are 
usually large.  There are many hereditary diseases, either monogenic or syndromic, that include 
hepatic steatosis as a clinical manifestation. Examples include inborn errors of metabolism, 
familial lipodystrophies, mitochondrial diseases, glycosylation, lysosomal and oxidative 
phosphorylation deficiencies.  Hereditary disorders associated with hepatic steatosis includes 
132 genes, among which are 32 loci associated with the pathogenesis of NAFLD in different 
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pathways and variants regulating lipid droplet (LD) biology, de-novo lipogenesis and fatty acid 
compartmentalization and the assembly and secretion of very low-density lipoproteins (VLDL) 
(Figure 1).  The causal role of these variants in the pathogenesis NAFLD has been validated by 
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Role of genetic variants in LD metabolic pathways (Figure 1)
 PNPLA3
The rs738409 C>G single nucleotide polymorphism (SNP), encoding for the I148M protein variant 
of Patatin-like phospholipase domain-containing 3 (PNPLA3), accounts for the largest fraction of 
genetic predisposition to NAFLD in all populations, and also accounts for the inter-ethnic 
variability in disease susceptibility (19).  The I148M variant is specifically associated with 
increased hepatic fat, but without a major direct impact on adiposity and insulin resistance (20), 
and while mouse models show no impaired secretion of VLDL (21), there is evidence to support 
defective VLDL secretion in humans (19, 22).  The PNPLA3 I148M variant increases susceptibility 
to the whole spectrum of progressive liver damage related to NAFLD (23-26) and functions as a 
common modifier of liver disease risk and progression (27-31).  Pathophysiological studies 
established that during obesity and insulin resistance PNPLA3 protein expression is induced in 
hepatocytes, hepatic stellate cells, and adipocytes, and is localized on LDs, where it represents 
the dominant surface protein (32, 33).  PNPLA3 has intrinsic lipase activity on triglycerides, 
phospholipids, and retinyl esters, mediating the hydrolytic production of oleate and other 
unsaturated fatty acids, including arachidonic acid (21, 33).  While the wild-type protein is rapidly 
degraded, the mutant protein cannot be ubiquitylated and consequently accumulates on the LD 
surface, simultaneously altering core lipid remodeling and turnover (21, 34-36).  The mutant 
I148M protein functions as a co-dominant negative rather than a loss-of-function allele, 
impairing LD hydrolysis (36, 37).  The mechanisms for impaired LD lipolysis with the mutant 
PNPLA3 I148M include sequestration of the required cofactor, 1 abhydrolase domain containing 
5 (ABHD5/CGI58) (Figure 1), that normally promotes lipolysis by adipose triglyceride lipase, 
ATGL/PNPLA2 (38, 39).  In addition, hepatocytes expressing mutant PNPLA3 exhibit defective 
autophagic flux and reduced lipophagy (40).  In combination, these defects promote steatosis, LD 
accumulation and NAFLD.  
The codominant negative function model for PNPLA3 I148M is supported by human genetics 
data, where carriage of another PNPLA3 variant (E434K), associated with reduced PNPLA3 
expression, mitigated LD accumulation produced by the 148M variant (21, 34, 35), whereas loss-
of-function PNPLA3 variants were not associated with severe liver disease (35).  Although the 
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protein on lipid droplets with trans-repression of ATGL (21, 34, 37, 41), carriage of the I148M 
variant is also associated with an alteration of lipid remodeling with accumulation of poly-
unsaturated fatty acids in DAG/TAGs and depletion in phospholipids, which is accounted for by 
reduced enzymatic activity (34, 42). Furthermore, the I148M variant impairs retinol release from 
hepatic stellate cells while also reducing LD abundance, a combination that promotes stellate cell 
activation, leading to inflammation, fibrogenesis, and carcinogenesis (33, 43, 44). Finally, the 
I148M variant may also modify adipocyte lipid metabolism and secretion of adipokines, which in 
turn may impact the liver phenotype (39, 45).  Other key players in LD lipolysis and turnover 
degradation have also been implicated directly in genetic forms of NAFLD, including mutant 
forms of ABHD5 which are associated with severe NAFLD in heterozygous adult subjects.  The 
underlying mechanisms likely reflect haploinsufficiency and progressive impairment in ABHD5 
protein activity (46), a prediction based on preclinical findings that liver-specific deletion of 
Abhd5/CGI-58 in mouse liver is associated with progressive NAFLD, NASH and fibrosis (47). 
 LAL
Isoforms of lysosomal acid lipase (LAL) arising from mutations in the LIPA gene are implicated in 
defective lysosomal LD turnover and early onset neutral lipid storage defects, promoting 
accumulation of hepatic cholesteryl esters and triglycerides due to defective lysosomal hydrolysis 
and impaired LD autophagy, causing a severe genetic form of NAFLD (Supplemental Table 1) (48).  
Homozygous LAL-D in its most severe form (<1% residual activity) causes neonatal 
hepatosplenomegaly and early onset liver failure (Wolman disease).  However, it remains unclear 
if heterozygous LIPA carriers are at risk for adult NAFLD and the carrier state may be much less 
common than previously thought. Earlier estimates indicated a carrier prevalence of 1:40,000 
while a recent survey of 120 known variants found the incidence to be <1:175,000, suggesting 
LAL-D is an extremely rare, albeit treatable condition, that should be considered as a secondary 
cause of NALFD (49).
 HSD17B13
Recent advances further illustrate the important role of LD remodeling in modifying the NAFLD 
phenotype. Specifically, variation in 17-beta hydroxysteroid dehydrogenase 13 (HSD17B13), 
which encodes an enzyme that localizes on LDs in hepatocytes, has been linked to protection 
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dysfunction or alcohol abuse disorder (50-54). HSD17B13 variants which protect against NAFLD 
progression are associated with reduced activity of the enzyme, with the original reports linking 
the association to reduced NASH but not to decreased hepatic steatosis (54), suggesting a loss-
of-function HSD17B13 allele impairs NAFLD progression rather than initiation (50, 51).  Those 
conclusions are consistent with other observations suggesting that the impact of the mutant 
HSD17B13 on reducing ALT levels was greater in subjects carrying mutant alleles (PNPLA3, 
TM6SF2) predisposing to hepatic steatosis (52).  The underling mechanisms linking mutant 
HSD17B13 with reduced progressive liver damage is unrelated to altering hepatic steatosis per 
se, but rather may reflect altered retinol metabolism and activation of fibrogenic and 
inflammatory pathways (53), although the cell-specific pathways (macrophage, stellate cell, 
hepatocyte) are yet to be elucidated.  Nevertheless, the available information points to 
therapeutic targeting of HSD17B13 as a strategy to mitigate progression of NAFLD.
Role of genetic variants in de novo lipogenesis, FA compartmentalization pathways
FA compartmentalization is used loosely to reflect substrate (FA) flow across multiple pathways 
and includes FA uptake, FA flux in the setting of de novo lipogenesis as well as FA reutilization in 
the setting of LD hydrolysis and remodeling.  The interconnected nature of these various settings 
is illustrated in Figure 1.  Genetic evidence has implicated lipid synthesis pathways in the 
pathogenesis of NAFLD, including variants in Glucokinase regulator (GCKR) expression (55-57). 
GCKR regulates de novo lipogenesis by modulating the influx of glucose into hepatocytes and 
consequently the flow of substrate for lipogenesis. Most data point to a common SNP 
(rs1260326), encoding for the P446L variant, as the causal variant underlying the association with 
fatty liver (58-60). This amino acid substitution impairs the ability of GCKR to inhibit glucokinase 
in response to fructose-6-phosphate, a response which represents a negative feedback loop 
controlling hepatic glucose uptake (58, 60).  The functional consequences for subjects harboring 
the P446L GCKR variant include decreased circulating glucose and heightened insulin sensitivity, 
which might portend net benefit, but at the same time the P446L variant increases hepatic 
production of malonyl-CoA, which promotes hepatic triglyceride accumulation by serving as a 
substrate for de novo lipogenesis and by blocking fatty acid oxidation, thus promoting hepatic 









This article is protected by copyright. All rights reserved
regulator (GCKR) gene has been reported in an adult patient with progressive NAFLD, morbid 
obesity, and type 2 diabetes (60). Hepatic GCKR protein expression was markedly decreased 
compared with NAFLD subjects who carry the wild-type allele. The presence of this mutation 
should be suspected as potentially associated with NAFLD, particularly in young adults with 
extreme histological phenotypes. 
Gene variation at the Protein phosphatase 1 regulatory subunit 3B (PPP1R3B) locus has also been 
suggested to protect against hepatic fat accumulation (13, 61, 62).  The mechanisms likely 
include increased PPP1R3B expression, which may cause metabolic redistribution of excess 
energy substrate towards glycogen instead of lipid synthesis (61). In particular, the rs4841132 
variant also resulted in decreased risk of progressive liver disease in individuals at high risk of 
NASH (61).  However, the overall impact of this variant on the risk of NAFLD and liver-related 
events remains controversial (62).
Insights into the importance of lipid remodeling in the pathogenesis of liver disease came from 
genome wide association studies (GWAS) evaluating susceptibility to alcohol related cirrhosis in 
European cohorts, highlighting the association of a variant close to (but not within) the 
Membrane bound O-acyltransferase domain-containing 7 (MBOAT7) locus (27).  The rs641738 
C>T variant was also associated with predisposition to hepatic steatosis and to develop 
progressive NAFLD with inflammation, fibrosis, and hepatocellular carcinoma (63, 64), although 
other studies concluded this variant does not confer increased NAFLD risk (65, 66). MBOAT7 is 
expressed in hepatocytes in the endoplasmic reticulum, and possibly lipid droplets during 
steatosis, and is involved in the remodeling of phosphatidylinositol and other phospholipids by 
incorporating arachidonic acid and other unsaturated fatty acids. The common rs641738 C>T 
variant linked to the 3’ untranslated region of the MBOAT7 has been linked with MBOAT7 
downregulation (63). In keeping with this prediction, impaired MBOAT7 expression results in 
reduced levels of phophatidylinositol containing arachidonic acid, both in hepatocytes and in the 
circulation (63, 67). Accumulating evidence show that downregulation of MBOAT7 expression is 
implicated in NAFLD development during obesity and insulin resistance and reflects altered 
phospholipid remodeling in hepatocellular lipid droplets, specifically lysophosphatidylinositol 
lipids, whose administration in mice directly promotes fibrogenic and inflammatory changes in an 
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of liver injury, including rs28929474, a low frequency variant in SERPINA1 (encoding alpha-1-
antitrypsin Pi*Z variant) as a putative risk factor for cirrhosis in patients with NAFLD who are of 
European descent (70).  However, earlier work showed that rs28929474 was not associated with 
severe liver damage in non-cirrhotic patients with NAFLD (71).
Role of genetic variants in VLDL assembly and secretion pathways (Figure 1)
Hepatic lipid export depends largely on the assembly and secretion of lipoproteins in a multistep 
process beginning in the rough and smooth endoplasmic reticulum (ER) with mobilization of LDs 
from within the bilayer into the ER lumen (Figure 1, lower inset).  This initial step requires an 
endoluminal transfer protein, microsomal triglyceride transfer protein (MTTP) and an acceptor 
protein, apolipoproteinB (APOB), mutations or deletions of which eliminate VLDL assembly and 
result in hepatic steatosis accompanied by extremely low levels of cholesterol and triglyceride in 
plasma (72).  MTTP is a resident endoluminal ER protein that functions as a heteromeric complex 
with a chaperone, protein disulfide isomerase, and transfers both neutral lipids (cholesterol and 
triglyceride) as well as phospholipid to the nascent APOB protein, thereby promoting assembly of 
a lipoprotein particle within the ER. These nascent particles become progressively enriched with 
neutral lipid and form a globular structure that transits through the ER and Golgi through 
tubulovesicular networks that eventually result in VLDL secretion into the Space of Disse.  
Genetic variants in APOB and MTTP cause autosomal codominant familial 
hypobetalipoproteinemia and autosomal recessive abetalipoproteinemia, respectively and 
represent rare genetic causes of NAFLD, cirrhosis and hepatocellular cancer (HCC) (73). In 2014, 
three groups simultaneously identified another genetic cause of hepatic steatosis and NAFLD, 
associated with defective VLDL assembly and secretion, namely a variant in TM6SF2 (74-76). 
Subjects with the rs58542926 variant TM6SF2 (E167K) exhibit a loss-of-function allele with 
defective VLDL secretion, reduced LDL levels (74-76), hepatic steatosis and fibrosis (77-80) .  
These studies are consistent in suggesting a model in which defective VLDL secretion results in 
hepatic steatosis, NAFLD and progressive liver disease, but reduced serum lipids and an improved 
risk profile for cardiovascular disease (76, 81).  However, basic mechanistic studies of VLDL 
secretion in global Tm6sf2 knockout mouse models have been inconsistent, with hepatic 
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in hepatic lipid and an unexplained increase in serum triglyceride levels (83). Paradoxically, 
adeno-associated or transgenic Tm6sf2 overexpression increased hepatic lipid content and 
decreased VLDL secretion in mice (83, 84).  But even those findings are inconsistent since other 
data show increased VLDL secretion with Ad-Tm6sf2 administration (75). The divergence in 
findings from these studies reflect an urgent need to understand the tissue-specific role of 
Tm6sf2 in hepatic VLDL secretion and fibrogenic injury.  Also, because data suggest that subjects 
with the rs58542926 variant are at increased risk for HCC, both in alcoholic cirrhosis (85, 86) and 
with NAFLD (63, 78), studies to examine pathways associated with HCC in association with 
TM6SF2 variants are also timely and relevant. 
Systems biology approaches to elucidating networks leading to NAFLD (Figure 2)
Research on NAFLD and NASH has grown exponentially in the past ten years, with ~ 20238 
(updated October 2019) biomedical articles available in the Medline and PubMed query interface 
associated with the terms “nonalcoholic fatty liver disease”, with an increase from 656 (2010) to 
2330 (2016) articles more recently (http://cbdm-01.zdv.uni-mainz.de/~jfontain/cms).  
Consequently, the concept of designating single mechanisms and/or single genes/proteins in 
NAFLD (as discussed above) has now evolved into exploration of multiple causal interactions 
using systems biology approaches. NAFLD represents a spectrum of histologic phenotypes with 
marked interindividual variability, as well as overlap with metabolic syndrome, and pleiotropy 
with other diseases (obesity, type 2 diabetes) as well as with several types of cancer (50, 87).  
These features suggest that mechanisms of pathogenesis might be elucidated by analyzing and 
modeling multiple NAFLD-genes and proteins into multiple, potentially overlapping networks.  
This notion of reclassifying disease using systems analysis or network medicine has significantly 
changed both diagnostic and therapeutic strategies directed towards complex traits (3, 4, 13, 88).  
We have taken an unbiased approach to interrogate multiple pathways and homeostatic 
interactions across thousands of proteins as a first step in identifying a potential role in NAFLD, a 
process that we refer to as the NAFLD-Reactome. The Reactome knowledgebase 
(https://reactome.org) provides a platform to investigate biological reactions in reactome 
functions (89) and systematically links human proteins to their molecular functions providing a 
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to extract information on genes and/or proteins through data mining and literature enrichment 
analysis. We sorted the pathways by fold enrichment values and selected for further analysis 
those with fold changes (FC) higher than 9.5.  This yielded 11 NAFLD-Reactome pathways that 
were further enriched (Table 1), including transport of small molecules –particularly, “plasma 
lipoprotein assembly, remodeling, and clearance”, metabolism, with enrichment of the sub-
pathway “integration of energy metabolism”, “metabolism of lipids”, and “the citric acid (TCA) 
cycle and respiratory electron transport”, signal transduction with enrichment of the sub-
pathway “signaling by receptor tyrosine kinases”, immune system with enrichment of the sub-
pathway  “innate immune system” and “cytokine signaling in immune system”, metabolism of 
proteins enriched of post-translational modifications and “regulation of beta-cell development”. 
8 out of the 11 NAFLD-Reactome pathways confirmed >100 terms from the original seed list, 
including metabolism of lipids, cytokine signaling in immune system, signal transduction, and 
metabolism of proteins.  These findings complement and extend the genetic evidence 
summarized above and suggest other wide-ranging effects of altered lipid metabolism in NAFLD, 
including macrophage, stellate cell signaling (90). 
As expected, the metabolism node (R-HSA-1430728.8) yielded the highest number of terms (n 
=280, adjusted p value 3.08E-54), followed by signal transduction (249, adjusted p value 5.79E-
23) and immune system (196, adjusted p value 1.09E-18). The large node represented by 
metabolism was also enriched in sub-pathways including “the citric acid/tricarboxylic acid (TCA) 
cycle and respiratory electron transport”, which included members of the mitochondrial 
transport carrier family such as uncoupling proteins, implicated in thermogenesis, fatty acid 
metabolism, and NAFLD-related comorbidities including obesity, diabetes and degenerative 
diseases.  Deregulation of the chemiosmotic gradient created by the TCA cycle and electron 
transport chain to drive ATP synthesis, which involves the export of protons across the inner 
mitochondrial membrane, may be crucial to NAFLD development and severity as suggested by 
preclinical (91) and human studies (11, 92, 93).
 
Network analysis predicted a node of immune system with sub-pathways including regulation of 
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of which has been associated with diabetes, atherosclerosis, renal failure and ageing.  Similarly, 
scavenging by Class B receptors sub-pathway as part of the major vesicle-mediated transport 
node was overrepresented reinforcing the concept that host-pathogen interactions and 
pathogen-associated molecular patterns are important players in NAFLD pathophysiology (94) as 
well as in the modulation of metabolic functioning and energy balance (95). In addition, analysis 
of NAFLD-Reactome pathways suggests that epigenetic mechanisms (96-98), including 
posttranslational protein modifications, are important in disease development. More 
importantly, these pathways are targets of intervention because they exhibit modifications with 
physical activity (96).  Among the sub-pathways that were overrepresented under the major 
node “Disease” we found overrepresentation of tumor suppressors (SMAD2/3 and TGFBR1), and 
Runt associated Transcription factor 3 (RUNX3) which is of interest because of findings showing 
hepatic RUNX3 is downregulated in NASH patients but not in alcoholic steatohepatitis (ASH) (14), 
a potential discriminator in differentiating of NAFLD and alcohol related fatty liver disease (99).
Pathways related to the regulation of beta-cell development were highly associated with NAFLD, 
particularly regulation of gene expression in beta cells and AKT-mediated inactivation of FOXO1 
(also known as FOXO1A).  Previous studies showed that FoxO1 (the mouse ortholog of FOXO1) 
regulates multiple metabolic functions in the liver, including gluconeogenic, glycolytic, and 
lipogenic gene expression pathways (100, 101). Finally, the node “organelle biogenesis and 
maintenance” was 17.1 fold-overrepresented, specifically, the sub-pathway “activation of 
PPARGC1A (PGC-1α) by phosphorylation”. A previous human study showed decreased PPARGC1A 
liver mRNA in patients with NAFLD as the consequence of gene promoter methylation (98).  
Tissue-specific epigenetic modifications in the PPARGC1A promoter also modulate mitochondrial 
mass and biogenesis, and directly impact glucose metabolism, in line with findings that patients 
with higher levels of promoter methylation exhibit greater insulin resistance (98).
 
To gain insights into the biological impact of all 344 Reactome pathways we plotted the weighted 
set of minimum subset NAFLD-genes/proteins, including all genes from the enriched sets with 
their P-value (Figure 2a). The volcano plot shows the negative log of the FDR versus the 
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which the significant categories stand out from the background (Figure 2a).  The NAFLD-
Reactome confirmed a role for genes associated with hereditary diseases-related hepatic 
steatosis, including a highly significant association with mitochondrial fatty acid beta-oxidation of 
saturated fatty acids with a 55-fold enrichment (p value 1.5e-8), (Supplementary Figure 1).  These 
findings underscore the utility of pathway analyses of NAFLD and provides important new 
insights into the role of hereditary disorders in the both the identification of causal variants and 
also potential pharmacological targets.  In addition, we used GO Cellular Components to search 
for the cell/tissue where gene/proteins in the NAFLD gene list are predicted to be preferentially 
localized (Figure 2b and Table 2).  Down-represented cell components (Table 2) reflect a paucity 
of hits in our data mining search which suggests these pathways are incompletely explored.  
Nevertheless, understanding of those downregulated pathways may offer an opportunity for 
future research because loci that are significantly associated with NAFLD may yet contain 
causative or modifier genes.
SUMMARY AND CONCLUSIONS
We recognize some limitations in our approach in using molecular networks to infer pathways in 
NAFLD pathogenesis, principally because the predicted pathways were constructed using existing 
data in Pubmed plus functional enrichment, both of which need to be experimentally validated. 
The hierarchy of the predicted pathways also requires formal experimental validation, although 
the available data from multiomics techniques support our major conclusions (102). 
Nevertheless, despite the potential constraints of data mining, the predicted NAFLD-Reactome 
pathways provides important new clues and insights into the genetic pathways involved in 
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Perspectives and key messages
 The analysis of pathways suggests that NAFLD results from the disruption to physiological mechanisms that 
regulate molecular homeostasis of lipoprotein complexes (LD formation/turnover/VLDL secretion).  Critical 
pathway nodes include: lipid particle organization, specifically the partitioning of neutral lipids from their 
site of synthesis at the endoplasmic reticulum to the cytosol. 
 The consequences of metabolic disturbances provoke adaptive changes in cellular energy levels, including 
TCA electron flux imbalance and impairment in proton transport capabilities.
 To accommodate hepatocyte perturbations in metabolism and energy balance, complex cell signaling 
processes that involve phosphorylation of tyrosine residues, STAT3 dimerization and nuclear translocation, 
insulin and G-protein coupled receptors–signaling as well as perturbations in endoplasmic reticulum 
(NOTCH), may contribute to disease-specific molecular modules. 
 NAFLD and cancer progression. Nodes associated with cellular proliferation, differentiation, and 
perturbation of tissue homeostasis, including transcription factors that modulate cell cycle, as well as 
growth factors and inflammatory cytokines. 
 Nodes associated with tumor suppressors are critically involved in NAFLD pathogenesis, as well as modules 
that highlight the importance of the immune system. 
Gaps between biology and translation  
 Knowledge on genes/proteins involved in NAFLD/NASH pathogenesis as well as locus involved in the genetic 
disease susceptibility is not yet fully understood. 
 Only a few – about 20%- of the reported genetic associations explain a substantial portion of trait 
heritability (85). Several explanations for this missing heritability have been proposed (85), including 
environmental factors and host-microbe interactions. Results from Reactome analysis suggested 
involvement of immune system, including innate immunity and cytokine signaling.
 Factors affecting epigenetic programs, including nutritional status and exposure to environmental toxins 
may contribute to heritability.    
 NAFLD-Reactome mapping may be exploited for future drug development. Enriched pathways contain 
gene/protein druggable targets. Also, integration of gene/protein into pathways may help to explore 
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FIGURE LEGENDS
Figure 1. Overview of genetic pathways in nonalcoholic fatty liver disease (NAFLD)
The major pathways involved in lipid trafficking, compartmentalization and utilization are 
represented within boxes, each of which undergo regulation through a combination of host 
genetic factors and environmental interactions (14).  Obesity and insulin resistance are each 
complex genetic traits, with variants in more than 1000 genes linked to altered susceptibility 
(106, 107).  Variations in energy metabolism are linked to variants in mitochondrial genes 
including uncoupling protein 1, 2 (UCP1, UCP2) as well as superoxide dismutase2 (SOD2), whose 
candidate genes are expressed in extrahepatic tissues (adipose, muscle) as well as the liver.  Fatty 
acid uptake and metabolic channeling results in partitioning between de novo lipogenesis/energy 
utilization/lipid droplet pathways.  Hepatic glucose uptake and utilization is also regulated by 
variants in glucokinase regulator (GCKR) (61), which in turn regulate substrate flow for de novo 
lipogenesis.  In addition, de novo lipogenesis pathways also interact metabolically with the very 
low density lipoprotein (VLDL) secretion pathway.  The lipid droplet (LD) pathway includes many 
of the candidate genes implicated in NAFLD development and progression, including patatin-like 
phospholipase domain-containing protein 3 (PNPLA3), abhydrolase containing domain 5 
(ABDH5), adipose triglyceride lipase (ATGL), hydroxysteroid 17--dehydrogenase B13 
(HSD17B13).  Those proteins are associated with LDs which contain a core of neutral lipids 
(triglyceride, TG and cholesterol ester, CE).  The VLDL pathway includes gatekeeper genes 
(microsomal triglyceride transfer protein, MTTP and apolipoprotein B, APOB, variants of which 
impair VLDL assembly within the endoplasmic reticulum (ER).  MTTP is an endoluminal ER protein 
that functions as an obligate heteromeric complex with protein disulfide isomerase (PDI) and 
together promote lipidation and correct folding of the APOB protein around a core of neutral 
lipid transferred from membrane associated and intraluminal LD.  In addition, variations in 
another transmembrane ER associated protein, transmembrane 6 superfamily 2 (TM6SF2) are 
associated with defective VLDL assembly and secretion (74, 75).  
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a) Volcano plot on NAFLD-predicted reactome pathways
Enrichment method: ORA (over representation analysis). Enrichment Categories: 
pathway_Reactome (data source: https://www.reactome.org/ and 
http://www.geneontology.org. Reference list: all mapped entrez gene IDs from the selected 
platform genome (61506entrezgene IDs and 10554 IDs are annotated to the selected functional 
categories that are used as the reference for the enrichment analysis.Organism: Homo sapiens. 
Parameters for the enrichment analysis: minimum number of IDs in the category: 5; maximum 
number of IDs in the category: 2000. FDR Method: Benjamini-Hochberg. Significance Level: Top 
200. The size and color of the dot is proportional to the number of overlapping (for ORA) or 
leading edge genes (for GSEA) of the category. ORA was performed by the WebGestalt (WEB-
based Gene SeTAnaLysis Toolkit) functional enrichment analysis web tool available at 
http://www.webgestalt.org/. Figure illustrates results of redundancy reduction (RR) of enriched 
gene sets; nevertheless, important biological pathways were all covered by the analysis. 
To identify the most representative and statistically significant gene sets for visualization, we 
used redundancy reduction and weighted set cover (99)
b) Figure ORA GO Slim Cellular component 
Cellular component was analyzed by PANTHER resource based on Gene ontology (GO) database. 
PANTHER GO-slim annotations represent only the subset of GO annotations that have been 
selected by curation (from available experimental annotations), and judged to be evolutionarily 
conserved(108)Fold-enrichment is calculated for each testing list as: (# genes for the category - # 
genes expected)/ # genes expected; broken lines are shown at 1 and -1 (no enrichments). The 
negative inverse of the fold-enrichment is used to show values below 1.  The -log transformation 
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Table 1: NAFLD-Reactome pathway analysis 
Reactome pathways 







1. Transport of small molecules (R-HSA-382551.5) 
1a.  Plasma lipoprotein assembly, remodeling, and clearance (R-HSA-174824.4) 
 HDL remodeling (R-HSA-8964058) 0.42 21.38 7.56E-07 
 Chylomicron clearance (R-HSA-8964026) 0.23 21.38 5.89E-04 
 LDL remodeling (R-HSA-8964041) 0.19 21.38 3.29E-03 
 Chylomicron remodeling (R-HSA-8963901) 0.47 19.24 1.20E-06 
 VLDL clearance (R-HSA-8964046) 0.28 17.82 9.96E-04 
 VLDL assembly (R-HSA-8866423) 0.23 17.1 5.02E-03 
 Plasma lipoprotein remodeling (R-HSA-8963899) 1.4 17.1 2.00E-16 
 Chylomicron assembly (R-HSA-8963888) 0.47 17.1 1.07E-05 
 Assembly of active LPL and LIPC lipase complexes (R-HSA-8963889) 0.84 14.25 1.00E-07 
 Plasma lipoprotein assembly, remodeling, and clearance (R-HSA-174824) 3.13 13.4 6.06E-26 
 Plasma lipoprotein clearance (R-HSA-8964043) 1.5 13.36 3.28E-12 
 Plasma lipoprotein assembly (R-HSA-8963898) 0.84 13.07 7.34E-07 
 LDL clearance (R-HSA-8964038) 0.89 11.25 6.95E-06 
 Triglyceride metabolism (R-HSA-8979227) 1.78 10.13 1.22E-09 
2. Metabolism (R-HSA-1430728.8) 
2a. Integration of energy metabolism (R-HSA-163685.1) 
 AMPK inhibits chREBP transcriptional activation activity (R-HSA-163680)  0.37 21.38 3.72E-06 
 ChREBP activates metabolic gene expression (R-HSA-163765) 0.33 15.27 1.61E-03 
2b. Metabolism of lipids (R-HSA-556833.6) 
 Import of palmitoyl-CoA into the mitochondrial matrix (R-HSA-200425) 0.65 18.33 1.60E-08 
 Lipid particle organization (R-HSA-8964572) 0.28 14.25 7.16E-03 
 Acyl chain remodeling of DAG and TAG (R-HSA-1482883)  0.37 13.36 2.44E-03 
 Triglyceride biosynthesis (R-HSA-75109) 0.65 12.22 5.57E-05 
 Recycling of bile acids and salts (R-HSA-159418) 0.75 12.03 1.67E-05 
 Biosynthesis of maresin-like SPMs (R-HSA-9027307) 0.28 10.69 4.30E-02 
 Synthesis of 15-eicosatetraenoic acid derivatives (R-HSA-2142770) 0.28 10.69 4.33E-02 
 Triglyceride metabolism (R-HSA-8979227) 1.78 10.13 1.22E-09 
2c. The citric acid (TCA) cycle and respiratory electron transport (R-HSA-1428517.1) 
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 The proton buffering model (R-HSA-167827) 0.23 12.83 3.21E-02 
 Mitochondrial Uncoupling Proteins (R-HSA-166187) 0.23 12.83 3.23E-02 
3. Signal transduction (R-HSA-162582.8) 
3a. Signaling by Receptor Tyrosine Kinase (R-HSA-9006934.4) 
 BetaKlotho-mediated ligand binding (R-HSA-1307965) 0.14 21.38 1.49E-02 
 MET activates STAT3 (R-HSA-8875791) 0.14 21.38 1.48E-02 
 IRS activation (R-HSA-74713) 0.23 17.1 5.04E-03 
 Signal attenuation (R-HSA-74749) 0.42 16.63 5.56E-05 
 MET activates PI3K/AKT signaling (R-HSA-8851907) 0.23 12.83 3.22E-02 
3b. Signaling by GPCR (R-HSA-372790.4) 
 Free fatty acid receptors (R-HSA-444209)  0.23 17.1 5.13E-03 
3c. Signaling by Leptin (R-HSA-2586552) 0.42 14.25 4.53E-04 
3d. Intracellular signaling by second messengers (R-HSA-9006925.3) 
 AKT phosphorylates targets in the nucleus (R-HSA-198693) 0.37 13.36 2.45E-03 
3e. Signaling by NOTCH (R-HSA-157118.4) 
 Pre-NOTCH Processing in the Endoplasmic Reticulum (R-HSA-1912399) 0.28 10.69 4.31E-02 
3f. Signaling by WNT (R-HSA-195721.5) 
 Binding of TCF/LEF:CTNNB1 to target gene promoters (R-HSA-4411364) 0.37 10.69 1.39E-02 
4. Immune system (R-HSA-168256.7) 
4a. Innate Immune System (R-HSA-168256.7) 
 Metal sequestration by antimicrobial proteins (R-HSA-6799990) 0.28 14.25 7.23E-03 
 Regulation of TLR by endogenous ligand (R-HSA-5686938)  0.89 12.38 1.01E-06 
 Advanced glycosylation end product receptor signaling (R-HSA-879415)  0.61 11.51 2.72E-04 
 Activation of C3 and C5 (R-HSA-174577)  0.33 12.22 1.01E-02 
4b. Cytokine Signaling in Immune system (R-HSA-1280215.4) 
 Activation of the AP-1 family of transcription factors (R-HSA-450341) 0.47 12.83 6.72E-04 
 Interleukin-1 processing (R-HSA-448706)  0.33 12.22 9.93E-03 
 Interleukin-10 signaling (R-HSA-6783783)  2.1 10.45 6.34E-12 
 Growth hormone receptor signaling (R-HSA-982772)  1.08 10.23 3.75E-06 
5. Metabolism of proteins (R-HSA-392499.7) 
5a. Peptide hormone metabolism (R-HSA-2980736.2) 
 Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) 
(R-HSA-381771)  0.94 10.69 9.68E-06 










This article is protected by copyright. All rights reserved 
 SUMOylation of intracellular receptors (R-HSA-4090294) 1.12 10.69 8.35E-07 
 Gamma-carboxylation of protein precursors (R-HSA-159740)  0.47 10.69 4.66E-03 
 Incretin synthesis, secretion, and inactivation (R-HSA-400508) 1.08 10.23 3.79E-06 
6. Disease (R-HSA-1643685.10) # 
6a. Signaling by TGF-beta Receptor Complex in Cancer (R-HSA-3304351.1) 
 SMAD2/3 Phosphorylation Motif Mutants in Cancer (R-HSA-3304356) 0.23 17.1 5.07E-03 
 Loss of Function of SMAD2/3 in Cancer (R-HSA-3304349) 0.28 14.25 7.20E-03 
 SMAD2/3 MH2 Domain Mutants in Cancer (R-HSA-3315487) 0.28 14.25 7.06E-03 
 Signaling by TGF-beta Receptor Complex in Cancer (R-HSA-3304351) 0.33 12.22 9.98E-03 
6b. Loss of Function of TGFBR2 in Cancer (R-HSA-3642278.1) 
 Loss of Function of TGFBR1 in Cancer (R-HSA-3656534) 0.28 14.25 7.13E-03 
 TGFBR1 KD Mutants in Cancer (R-HSA-3656532) 0.28 14.25 7.09E-03 
6c. Diseases of glycosylation (R-HSA-3781865.1) 
 Defective LFNG causes SCDO3 (R-HSA-5083630) 0.23 12.83 3.26E-02 
6d. Diseases of Immune System (R-HSA-5260271.1) 
 IkBA variant leads to EDA-ID (R-HSA-5603029)  0.33 12.22 1.00E-02 
 MyD88 deficiency (TLR2/4) (R-HSA-5602498)  0.47 10.69 4.63E-03 
 
 
7. Gene expression (R-HSA-74160.7) 
7a. Transcriptional regulation by RUNX3 (R-HSA-8878159.2) 
 RUNX3 regulates CDKN1A transcription (R-HSA-8941855) 0.33 12.22 1.01E-02 
 RUNX3 regulates WNT signaling (R-HSA-8951430) 0.37 10.69 1.38E-02 
 Nuclear Receptor transcription pathway (R-HSA-383280) 1.82 9.87 1.61E-09 
8. Hemostasis (R-HSA-109582.2) 
8a. Formation of Fibrin Clot (Clotting Cascade) (R-HSA-140877.2) 
 Extrinsic Pathway of Fibrin Clot Formation (R-HSA-140834.2)  0.23 12.83 3.24E-02 
9. Developmental Biology (R-HSA-1266738.5) 
9a. Regulation of beta-cell development (R-HSA-186712.2) 
 AKT-mediated inactivation of FOXO1A (R-HSA-211163)  0.19 16.04 2.21E-02 
 Regulation of gene expression in beta cells (R-HSA-210745)  0.89 11.25 6.88E-06 
10. Vesicle-mediated transport (R-HSA-5653656.2) 
10a. Binding and Uptake of Ligands by Scavenger Receptor (R-HSA-2173782.1) 
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11. Organelle biogenesis and maintenance (R-HSA-1852241.5) 
11a. Mitochondrialbiogenesis (Homo sapiens) R-HSA-1592230.2 
 Activation of PPARGC1A (PGC-1alpha) by phosphorylation (R-HSA-
2151209)  0.47 17.1 1.06E-05 
 
Table 1, legend.  We used the following analysis types: PANTHER Overrepresentation Test 
(Released 20190711); annotation version and release date: Reactome version 65 released 2019-
03-12; reference list: Homo sapiens (all genes in database) REFLIST (20996). Test: Fisher's exact 
adjusted by multiple testing (FDR: False Discovery Rate). Seed list: data mining NAFLD (1005 
genes/proteins from data mining). Results are restricted to fold enrichment >9.5. #From the 
viewpoint of molecular pathogenesis, human disease pathways in the Reactome database have 
three mechanistic causes: (1) the inclusion of microbially-expressed proteins, (2) altered 
function of human proteins, or (3) changed expression levels of otherwise functionally normal 
human proteins. In The Reactome Knowledgebase (https://reactome.org), pathways are 
organized hierarchically, which include pathways events or steps, known as reactions. Table 1 
shows the uppermost hierarchical level as pathways nodes, which are numbered consecutively 
from 1 to 11. Sub-pathways that rank into major nodes are shown under the corresponding 
node and sub-sub pathways that rank into the sub-pathways are shown under the 
corresponding sub-pathway. Data mining and literature enrichment analysis used the following 
sources: Genie web server (http://cbdm.uni-mainz.de/genie), a tool that computes associations 
of genes with keywords using biomedical literature annotations. The training set included 919 
abstracts from PubMed in a background set that involved abstracts from the all PubMed 
database. Key words: NAFLD and NASH and Mesh terms. Cutoffs were set as 0.01 for abstracts, 
and false discovery rate<0.01 for genes. A list of 1005 terms (genes/proteins) was constructed, 
which was used as training list for further systems biology assessment. Reactome pathways 
used the following sources: PANTHER (protein annotation through evolutionary relationship 
http://pantherdb.org). Briefly, the statistical test for over- and underrepresentation determines 
whether a given (functional) class is found statistically more (or less) often in the input list, than 
expected by chance taking the representation of the pathways genes in the entire human 
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genes/proteins are significantly enriched. The input values were compared to the distribution 
of all human proteins available in the dataset (~15 000 families of proteins) using Fisher's exact 
test. Both the overrepresentation test and the enrichment test used the Benjamini-Hochberg's 
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Table 2: GO Cellular Components Associated with NAFLD Genes 
PANTHER GO-Slim Cellular Component P value 
GO Lipid droplet 
CIDEC (cell death activator CIDE-3) 
1.55 E-06 
ABHD5 (abhydrolase domain containing 5) 
PNPLA2 
HILPDA (hypoxia-inducible lipid droplet-associated protein) 
PLIN4 (perilipin-4) 
CIDEB (cell death activator CIDE-B) 
CIDEA (cell death activator CIDE-A) 
PNPLA3 
HSD17B13 (hydroxy steroid 17-beta dehydrogenase 13) 
GO Protein kinase complex 
CHUK (inhibitor of nuclear factor kappa-B kinase subunit alpha) 
3.57 E-04 
IGF1R (insulin-like growth factor 1 receptor) 
PRKAB1 (5'-AMP-activated protein kinase subunit beta-1) 
TGFBR1 (TGF-beta receptor type-1) 
PRKAB2 (5'-AMP-activated protein kinase subunit beta-2) 
INSR (insulin receptor) 
IKBKB (inhibitor of nuclear factor kappa-B kinase subunit beta) 
RNA polymerase II transcription II factor complex 
NR5A2 (nuclear receptor subfamily 5 group A member 2) 
1.03 E-06 
PPARG (peroxisome proliferator-activated receptor gamma) 
VDR (vitamin D3 receptor) 
NR1I2 (nuclear receptor subfamily 1 group I member 2) 
RARA (retinoic acid receptor alpha) 
PPARD (peroxisome proliferator-activated receptor delta) 
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NR1H3 (oxysterols receptor LXR-alpha) 
PPARA (peroxisome proliferator-activated receptor alpha) 
NR1H4 (FXR, bile acid receptor) 
E2F1 (transcription factor E2F1) 
NR1I3 (nuclear receptor subfamily 1 group I member 3) 
NR1D2 (nuclear receptor subfamily 1 group D member 2) 
Nuclear lumen 
OAS1 (2'-5'-oligoadenylate synthase 1 8.02 E-04 
TP53 (cellular tumor antigen p53) 
NFKB1 (nuclear factor NF-kappa-B p105 subunit) 
MSL2 (E3 ubiquitin-protein ligase MSL2) 
ADARB2 (double-stranded RNA-specific editase B2) 
JUN (Transcription factor AP-1) 
SPTY2D1 (protein SPT2 homolog) 

















DLG4 (lethal(2) giant larvae protein homolog 1) 
WDR1 (WD repeat-containing protein 1) 
ALMS1 (Alstrom syndrome protein 1) 
ADD1 (alpha-adducin) 
DNAH11 (dynein heavy chain 11, axonemal) 
MYO1B (unconventional myosin-Ib) 
SLC27A4 (long-chain fatty acid transport protein 4) 
ADD3 (gamma-adducin) 
Nuclear transcription factor complex (GO:0044798) 1.24E-04 
Extracellular space (GO:0005615) 8.39E-17 
Extracellular region part (GO:0044421) 2.03E-17 
Extracellular region (GO:0005576) 1.01E-18 
Intracellular (GO:0005622) 6.08E-04 
Cell part (GO:0044464) 2.72E-04 
Cell (GO:0005623) 3.69E-04 
Microtubule cytoskeleton (GO:0015630) 4.82E-05 
 





















a Enrichment Categories: Pathway Reactome
b GO Slim Cellular Component 
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